Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Ruminant Vaccines Market Size & Forecasts 2026-2035, By Segments (Vaccine Type, Disease Type, Animal Type, Route of Administration, End-user), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale)
Market Size and Growth Outlook
Base Year Value (2025)
USD 2.14 Billion
CAGR (2026-2035)
6.9%
Forecast Year Value (2035)
USD 4.17 Billion
Historical Data Period
2021-2025
Largest Region
North America
Forecast Period
2026-2035
Key Takeaways
- North America region acquired over 39.1% revenue share in 2025, supported by strong livestock health focus.
- Asia Pacific region will register more than 8% CAGR during the forecast period, attributed to growing livestock farming.
- Capturing 68.6% ruminant vaccines market share in 2025, cattle segment expanded its dominance, supported by large cattle population drives cattle vaccine dominance.
- The injectable segment reached 77.6% revenue share in 2025, fueled by established delivery drives injectable dominance.
- With 54.45% market share in 2025, inactivated vaccines segment’s growth was led by safety profile drives inactivated vaccine dominance.
- Top companies in the ruminant vaccines market comprise Zoetis (USA), Merck Animal Health (USA), Boehringer Ingelheim (Germany), Elanco (USA), Ceva Santé Animale (France), Virbac (France), HIPRA (Spain), Hester Biosciences (India), Vetoquinol (France), Indian Immunologicals (India).
Market Growth Drivers and Industry Trends
Rising Prevalence of Livestock Diseases Driving Preventive Vaccination
The increasing incidence of livestock diseases, such as foot-and-mouth disease and bovine viral diarrhea, has heightened awareness among farmers and livestock owners regarding the importance of preventive vaccination. The World Organisation for Animal Health (OIE) reports that outbreaks of these diseases not only threaten animal health but also significantly impact food security and economic stability. As a result, the ruminant vaccines market is witnessing a surge in demand for effective vaccination solutions. This trend opens avenues for established players to innovate and enhance their product offerings while providing new entrants the opportunity to develop specialized vaccines targeting specific diseases, thereby capturing niche segments of the market.
Technological Advancements in Vaccine Delivery Systems
Innovations in vaccine delivery systems, including needle-free injection technologies and microencapsulation, are transforming how vaccines are administered to ruminants. These advancements not only improve the efficacy and safety of vaccines but also enhance ease of use for farmers, leading to higher vaccination rates. According to research from the Food and Agriculture Organization (FAO), efficient delivery mechanisms can significantly reduce stress on animals during vaccination, promoting better overall health outcomes. This technological evolution in the ruminant vaccines market presents strategic opportunities for both established companies to upgrade their delivery methods and new players to introduce cutting-edge solutions that cater to the evolving needs of livestock producers.
Expansion of Government Livestock Health Programs
Government initiatives aimed at enhancing livestock health are increasingly becoming pivotal in shaping the ruminant vaccines market. Programs such as the U.S. Department of Agriculture’s (USDA) Animal Health Program focus on disease prevention through vaccination campaigns and educational outreach to farmers. These efforts not only bolster public health but also incentivize the adoption of vaccines, creating a robust market environment. The expansion of such programs offers established players the chance to secure government contracts while providing startups with the potential to align their offerings with governmental health priorities, thereby ensuring compliance and gaining market access in a rapidly evolving landscape.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of livestock diseases driving preventive vaccination | 2.20% | Short term (≤ 2 yrs) | Asia Pacific, North America (spillover: Europe) | High | Fast |
| Technological advancements in vaccine delivery systems | 1.40% | Medium term (2–5 yrs) | Europe, North America (spillover: Latin America) | Medium | Moderate |
| Expansion of government livestock health programs | 1.00% | Long term (5+ yrs) | MEA, Asia Pacific (spillover: Europe) | High | Slow |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regulatory Compliance Burdens
The ruminant vaccines market faces significant constraints due to stringent regulatory compliance requirements imposed by authorities such as the European Medicines Agency (EMA) and the U.S. Department of Agriculture (USDA). These regulations necessitate extensive testing and validation processes, often leading to increased operational costs and extended timelines for product development. For instance, the EMA mandates comprehensive safety and efficacy trials for veterinary vaccines, which can delay market entry and stifle innovation. The complexity of navigating these regulatory landscapes creates a barrier for new entrants, who may lack the resources or expertise to meet such rigorous standards, consequently limiting competition and slowing technological advancements. As the industry grapples with these compliance burdens, established companies may find themselves investing heavily in regulatory affairs, diverting resources from research and development initiatives that could drive market growth.
Supply Chain Vulnerabilities
Another critical restraint impacting the ruminant vaccines market is the vulnerability of supply chains, exacerbated by global disruptions such as the COVID-19 pandemic. The reliance on a limited number of suppliers for raw materials and the complexity of logistics can lead to significant delays and increased costs. For example, the Animal Health Industry Association has reported that disruptions in raw material availability have led to production halts for several vaccine manufacturers. This fragility not only affects established players who may face production delays but also deters new entrants who are wary of the risks associated with supply chain instability. As companies strive to enhance resilience, the focus on local sourcing and diversified supply chains is likely to intensify. In the near to medium term, these supply chain challenges will continue to shape market dynamics, pushing companies to innovate in logistics and inventory management to mitigate risks and ensure consistent vaccine availability.
Regional Demand Dynamics
Largest Region
North America
39.1% Market Share in 2025
North America Market Statistics:
North America represented more than 39.1% of the global ruminant vaccines market in 2025, establishing itself as the largest region. This dominance can be attributed to a robust focus on livestock health, driven by increasing consumer awareness of food safety and animal welfare. The region's advancements in veterinary science and technology have fostered innovative vaccine development, aligning with heightened sustainability priorities and evolving regulatory frameworks. Additionally, the competitive intensity among leading vaccine manufacturers has spurred operational efficiencies and enhanced supply chain logistics. As a result, North America presents significant opportunities for growth in the ruminant vaccines market, supported by a resilient economic landscape and a commitment to animal health initiatives, as highlighted by the American Veterinary Medical Association.
The United States anchors the North American ruminant vaccines market, characterized by a strong emphasis on livestock health and preventive care. The country's regulatory environment, shaped by the U.S. Department of Agriculture and the Food and Drug Administration, ensures stringent safety and efficacy standards for vaccine development. This regulatory clarity has enabled companies like Zoetis to innovate and bring advanced ruminant vaccines to market, responding to increasing consumer demand for healthier livestock and safer food products. Furthermore, the cultural dynamics surrounding animal husbandry in rural America reinforce the importance of effective vaccination strategies, ensuring livestock productivity and profitability. As such, the U.S. not only leads in market share but also exemplifies a model for other nations in the region, driving overall growth in the ruminant vaccines market.
Canada complements the North American ruminant vaccines market with its own unique strengths, particularly in sustainable agricultural practices. The Canadian Food Inspection Agency plays a pivotal role in regulating vaccine use, promoting biosecurity measures that resonate with consumer preferences for ethically sourced animal products. Companies like Merck Animal Health are actively engaged in addressing the specific needs of Canadian livestock producers, focusing on vaccines that enhance herd immunity and reduce disease prevalence. The cultural appreciation for sustainable farming and animal welfare in Canada aligns with the broader regional trends, further solidifying North America's leadership in the ruminant vaccines market. Together, these country-specific dynamics not only reinforce the region's dominance but also highlight a collaborative approach to advancing livestock health and vaccination strategies.
Asia Pacific Market Analysis:
Asia Pacific emerged as the fastest-growing region in the ruminant vaccines market, registering rapid growth with a robust CAGR of 8%. This impressive growth can be attributed to the increasing demand for livestock farming, driven by rising meat consumption and the need for enhanced animal health management. The region's significant investment in agricultural biotechnology and vaccine development is further propelling the market forward, as stakeholders prioritize animal welfare and productivity. Additionally, the shift towards sustainable farming practices is influencing consumer preferences, leading to a heightened focus on effective vaccination strategies to ensure livestock health and productivity. Recent reports from the Food and Agriculture Organization (FAO) highlight that Asia Pacific is home to a large proportion of the world's livestock, underscoring the critical need for effective vaccination solutions to combat diseases and enhance food security. As the region continues to innovate and adapt to changing agricultural demands, it presents substantial opportunities for growth in the ruminant vaccines market.
Japan plays a pivotal role in the Asia Pacific ruminant vaccines market, characterized by its advanced agricultural practices and stringent regulatory frameworks. The growing livestock farming sector in Japan is increasingly embracing innovative vaccination solutions to address both productivity and animal welfare concerns. With a strong emphasis on food safety and quality, Japanese farmers are adopting vaccines that not only enhance livestock health but also align with consumer expectations for higher-quality meat products. The Ministry of Agriculture, Forestry and Fisheries (MAFF) has been proactive in promoting vaccination programs, resulting in a more resilient livestock sector. This strategic focus on health management is crucial for Japan's competitive positioning in the regional market, reflecting a broader trend towards sustainable practices that resonate with consumers.
China, as another major player in the Asia Pacific ruminant vaccines market, is experiencing a transformation in its livestock sector, driven by the growing demand for meat products and evolving consumer preferences. The country’s rapid urbanization and increasing disposable incomes are fueling higher meat consumption, prompting farmers to invest in advanced vaccination technologies. The Chinese government has implemented supportive policies aimed at enhancing animal health and productivity, including subsidies for vaccination programs. According to the Ministry of Agriculture and Rural Affairs, these initiatives have led to improved disease control and better overall livestock health. As a result, China is not only strengthening its ruminant vaccines market but also setting a precedent for innovation and efficiency in livestock management. The interplay of these factors positions China as a critical contributor to the region's growth, reinforcing the Asia Pacific's leadership in the global ruminant vaccines market.
Europe Market Trends:
The ruminant vaccines market in Europe holds a commanding share, driven by a combination of robust agricultural practices and increasing awareness around animal health. This region is significant due to its advanced livestock management systems and stringent regulatory frameworks, which prioritize animal welfare and food safety. Recent shifts in consumer preferences towards sustainably sourced animal products have propelled investments in innovative vaccine solutions, enhancing market dynamics. For instance, the European Commission's ongoing initiatives to support sustainable agriculture underscore the importance of vaccination in disease prevention and productivity enhancement. As a result, the European ruminant vaccines market is poised for continued growth, presenting substantial opportunities for stakeholders.
Germany plays a pivotal role in the European ruminant vaccines market, characterized by its strong agricultural sector and commitment to animal health. The country's emphasis on biosecurity and disease management has led to increased adoption of advanced vaccine technologies. The Federal Ministry of Food and Agriculture highlights initiatives aimed at improving livestock health through vaccination, which aligns with growing consumer demand for high-quality meat and dairy products. This focus on innovation not only addresses immediate health concerns but also enhances the overall competitiveness of German livestock products in the international market. Consequently, Germany's proactive stance in vaccine adoption positions it as a key player in driving regional growth in the ruminant vaccines market.
France, similarly, maintains a notable presence in the ruminant vaccines market, bolstered by its diverse livestock production and strong regulatory support. The French Ministry of Agriculture emphasizes the critical role of vaccination in maintaining herd health and productivity, reflecting a cultural commitment to animal welfare that resonates with consumers. The country has witnessed increased investment in research and development of novel vaccines, driven by both domestic demand and export opportunities. For example, the French veterinary pharmaceutical company Ceva Santé Animale has made significant strides in vaccine innovation, contributing to the overall growth of the market. As France continues to enhance its vaccine offerings, it reinforces its strategic importance in the European ruminant vaccines landscape, creating pathways for collaborative advancements across the region.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Nascent |
| Cost-Sensitive Region | Medium | High | Medium | High | High |
| Regulatory Environment | Supportive | Neutral | Restrictive | Neutral | Neutral |
| Demand Drivers | Strong | Moderate | Strong | Moderate | Weak |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | High | Medium | High | Medium | Low |
| New Entrants / Startups | Dense | Moderate | Dense | Sparse | Sparse |
| Macro Indicators | Strong | Stable | Stable | Stable | Weak |
Segment Leadership and Growth Trends
Analysis by Animal Type
The ruminant vaccines market for cattle dominated the segment with a commanding 68.6% share in 2025. This leadership is primarily attributed to the large cattle population, which necessitates robust vaccination programs to ensure herd health and productivity. The increasing focus on sustainable livestock practices and the growing demand for high-quality beef and dairy products have further fueled the adoption of cattle vaccines. As noted by the Food and Agriculture Organization (FAO), effective vaccination strategies are critical in enhancing food security and animal welfare, providing strategic advantages for both established firms and emerging players in this segment. With ongoing advancements in vaccine formulations and delivery methods, the cattle segment is expected to maintain its relevance in the near to medium term, driven by continuous innovations and regulatory support.
Analysis by Route of Administration
The ruminant vaccines market for injectable vaccines captured over 77.6% share of the route of administration segment in 2025. This dominance stems from the established delivery mechanisms that ensure effective immunization and ease of use for veterinarians and farmers alike. The preference for injectable vaccines is reinforced by their proven efficacy and the ability to target multiple diseases simultaneously, aligning with the industry's push for comprehensive health management in livestock. According to the World Organisation for Animal Health (OIE), effective vaccination practices are essential for disease control, presenting significant opportunities for market players to innovate and expand their product offerings. As the industry increasingly embraces digital transformation in vaccine management, the injectable segment is poised to remain a cornerstone of the ruminant vaccines market.
Analysis by Vaccine Type
The ruminant vaccines market for inactivated vaccines represented more than 54.4% of the vaccine type segment in 2025. The safety profile of inactivated vaccines is a key factor driving this segment's leadership, as they are widely regarded as safe for use in various age groups of livestock. The growing awareness among farmers regarding animal health and food safety has led to a preference for these vaccines, which are less likely to cause adverse reactions. The American Veterinary Medical Association (AVMA) highlights that inactivated vaccines play a crucial role in preventing outbreaks, thereby enhancing the market's appeal. This segment offers strategic advantages for both established firms and new entrants, particularly as awareness of vaccination's importance continues to rise. With ongoing research and development efforts focused on improving efficacy and reducing costs, inactivated vaccines are expected to remain a vital component of the ruminant vaccines market.
| Report Segmentation | |
| Segment | Sub-Segment |
|---|---|
| Vaccine Type | Inactivated vaccines, Attenuated/modified live vaccines, Other vaccine types |
| Disease Type | Bovine respiratory diseases (BRD), Clostridial diseases, Bovine viral diarrhea (BVD) infection, Foot-and-mouth disease (FMD), Leptospirosis, Diarrhea/Scours, Rift valley fever (RVF), Other disease types |
| Animal Type | Cattle, Sheep & goats |
| Route of Administration | Injectable, Intranasal |
| End-user | Veterinary hospitals & clinics, Livestock farms, Research institutes |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
Key players in the ruminant vaccines market include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, Virbac, HIPRA, Hester Biosciences, Vetoquinol, and Indian Immunologicals. These companies are recognized for their innovative approaches and extensive product portfolios, which have positioned them as leaders in the industry. For instance, Zoetis and Merck Animal Health leverage their significant research capabilities to introduce advanced vaccine formulations, while Boehringer Ingelheim and Elanco focus on integrating cutting-edge technologies to enhance vaccine efficacy. The prominence of these players is further underscored by their strong global presence and commitment to addressing the evolving needs of livestock health management.
The competitive landscape of the ruminant vaccines market is characterized by dynamic strategic initiatives that reflect the companies' commitment to innovation and market leadership. Collaborations and alliances among these top players are frequently observed, facilitating the sharing of expertise and resources to accelerate product development. New product introductions, particularly those that incorporate novel delivery mechanisms or target specific diseases, have been pivotal in maintaining competitive advantages. Furthermore, significant investments in research and development are evident, as companies like Ceva Santé Animale and Virbac strive to enhance their technological capabilities, thereby shaping the overall market environment and fostering a culture of continuous improvement.
Strategic / Actionable Recommendations for Regional Players
In North America, leveraging partnerships with local agricultural institutions could enhance research initiatives, fostering innovation in vaccine development tailored to regional livestock health challenges. Emphasizing the integration of emerging technologies, such as digital health monitoring systems, can significantly improve vaccine delivery and efficacy. In the Asia Pacific region, targeting high-growth sub-segments, such as smallholder farms, through affordable and accessible vaccine solutions can capture a larger market share and address local health concerns effectively. In Europe, responding proactively to competitive initiatives by forming strategic alliances with biotechnology firms may enhance product offerings and expand market reach, ensuring sustained growth and relevance in a rapidly evolving landscape.
| Competitive Dynamics and Strategic Insights | ||
| Assessment Parameter | Assigned Scale | Scale Justification |
|---|---|---|
| Market Concentration | High | The market is dominated by Zoetis, Merck, and Boehringer Ingelheim. |
| M&A Activity / Consolidation Trend | Active | Acquisitions (e.g., Merck’s 2024 aqua business purchase) enhance vaccine portfolios. |
| Degree of Product Differentiation | High | Vaccines vary for diseases like FMD, brucellosis, and clostridial infections. |
| Competitive Advantage Sustainability | Durable | Regulatory approvals and R&D expertise create strong barriers. |
| Innovation Intensity | High | Advances in recombinant and inactivated vaccines drive R&D for ruminant health. |
| Customer Loyalty / Stickiness | Strong | Livestock producers rely on proven vaccines for herd health and productivity. |
| Vertical Integration Level | Medium | Manufacturers control R&D and production, but distribution often involves third parties. |
Frequently Asked Questions
How big is the ruminant vaccines market?
The market size of ruminant vaccines in 2026 is calculated to be USD 2.27 billion.
What is the expected industry size of ruminant vaccines by 2035?
Ruminant Vaccines Market size is estimated to increase from USD 2.14 billion in 2025 to USD 4.17 billion by 2035, supported by a CAGR exceeding 6.9% during 2026-2035.
In which region is the ruminant vaccines industry share the greatest?
North America region acquired over 39.1% revenue share in 2025, supported by strong livestock health focus.
Where has the ruminant vaccines sector recorded the sharpest year-over-year increase?
Asia Pacific region will register more than 8% CAGR during the forecast period, attributed to growing livestock farming.
How much is the cattle expected to grow in the ruminant vaccines industry beyond 2025?
Capturing 68.6% ruminant vaccines market share in 2025, cattle segment expanded its dominance, supported by large cattle population drives cattle vaccine dominance.
What factors give injectable a competitive edge in the ruminant vaccines sector?
The injectable segment reached 77.6% revenue share in 2025, fueled by established delivery drives injectable dominance.
Which is the largest sub-segment within the vaccine type segment for ruminant vaccines industry?
With 54.45% market share in 2025, inactivated vaccines segment’s growth was led by safety profile drives inactivated vaccine dominance.
Who are the major participants shaping the ruminant vaccines landscape?
Top companies in the ruminant vaccines market comprise Zoetis (USA), Merck Animal Health (USA), Boehringer Ingelheim (Germany), Elanco (USA), Ceva Santé Animale (France), Virbac (France), HIPRA (Spain), Hester Biosciences (India), Vetoquinol (France), Indian Immunologicals (India).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
